Safety, efficacy and survival of patients (pts) with primary CNS tumors in phase 1 (Ph1) trials: A 12-year single institution experience.-Reference-Cited by-同舟云学术

Safety, efficacy and survival of patients (pts) with primary CNS tumors in phase 1 (Ph1) trials: A 12-year single institution experience.

Published:2016-05-20 Issue:15_suppl Volume:34 Page:2043-2043
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Coleman Niamh¹,Michalarea Vasiliki²,Alken Scheryll Paula³,Rihawi Karim⁴,Greenwood Kathy⁵,Perez Lopez Raquel⁶,Tunariu Nina⁷,Yap Timothy Anthony⁸,Banerji Udai⁹,De Bono Johann S.¹⁰,Welsh Liam¹,Molife L. Rhoda¹¹,Saran Frank¹²,Lopez Juanita¹³

Affiliation:

1. Royal Marsden Hospital, London, United Kingdom;

2. The Royal Marsden Hospital NHS Foundation Trust and The Institute of Cancer Research, Sutton, United Kingdom;

3. Royal Marsden Hospital, Sutton, United Kingdom;

4. University Hospital of Udine, Udine, Italy;

5. Department of NeuroOncology, Royal Marsden NHS Foundation Trust, Sutton, United Kingdom;

6. Institute of Cancer Research, London, United Kingdom;

7. Drug Development Unit, Royal Marsden Hospital and The Institute of Cancer Research, London, United Kingdom;

8. Royal Marsden NHS Foundation Trust, London, United Kingdom;

9. The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Sutton, United Kingdom;

10. The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, United Kingdom;

11. The Royal Marsden Hospital NHS Foundation Trust and The Institute of Cancer Research, London, United Kingdom;

12. The Royal Marsden NHS Foundation Trust, Surrey, United Kingdom;

13. The Royal Marsden/Institute of Cancer Research, Sutton, United Kingdom;

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2016.34.15_suppl.2043

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach;Clinical Medicine Insights: Oncology;2018-01-01

2. Outcome of children and adolescents with central nervous system tumors in phase I trials;Journal of Neuro-Oncology;2017-12-13